Actively Recruiting
Using Multiparametric MRI to Predict Early Response to Chemotherapy in Muscle-Invasive Bladder Cancer Patients
Led by Assiut University · Updated on 2025-10-02
39
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Muscle-invasive bladder cancer MIBC is a common and serious form of bladder cancer with a five-year survival rate below 50%. Neoadjuvant chemotherapy NAC before surgery has shown benefits for patients with resectable MIBC, but some patients do not respond and may face delayed surgery and unnecessary side effects. This research evaluates whether early changes seen on multiparametric magnetic resonance imaging mpMRI can predict how well patients respond to NAC, aiming to improve personalized treatment plans. Participants with MIBC receiving standard neoadjuvant chemotherapy with gemcitabine and cisplatin will have three mpMRI scans before starting chemotherapy, 24 hours after the first cisplatin dose, and after completing chemotherapy but before surgery. The imaging will include techniques to assess tumor blood flow and tissue characteristics, focusing on biomarkers like Ktrans, Ve, and the apparent diffusion coefficient ADC to detect early changes linked to treatment response. During the study, researchers will compare imaging results with surgical pathology outcomes after radical cystectomy to see how well early mpMRI changes predict treatment success. Participants will undergo these imaging scans alongside their standard chemotherapy and surgery schedule. The main measurement is the predictive value of these imaging biomarkers from baseline to surgery, approximately 8 to 10 weeks later, helping to tailor future treatments and avoid ineffective chemotherapy.
CONDITIONS
Brief Title
Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
Research Team
H
Hamza mohamed, MBBCh
A
Amr Darwish, Lecturer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here